IP Library Granted Patent US 11,739,347
Granted Patent B2
US 11,739,347 · App. 16/719,251 · Granted Aug 29, 2023

Adeno-associated virus (AAV) producer cell line and related methods

Inventors: Bingnan Gu (Manvel, TX); Caitlin M. Guenther (Houston, TX); Anandita Seth (Sugar Land, TX)
Assignee: LONZA WALKERVILLE, INC.
C12N15/86C12N15/113C12N15/8645C12N2710/10343C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,739,347
App. No.
16/719,251
Granted
Aug 29, 2023
Kind
B2
Abstract

The present disclosure relates to a mammalian cell line for producing adeno-associated virus (AAV), suitably including nucleic acids encoding helper genes and AAV genes, under the control of derepressible promoters. The disclosure also relates to isolated nucleic acid molecules that encode such genes, as well as methods of using the mammalian cells for producing AAVs.

Claims (28)

1. An isolated nucleic acid molecule comprising a plasmid encoding, in operable order:

a. a derepressible p5 promoter;

b. a rep78 gene, including a silenced p19 promoter located within the rep78 gene coding region, wherein the silenced p19 promoter comprises mutations in the SP1, TATA-1, and TATA-2 sites of a p19 promoter;

c. a cap gene;

d. a p5 promoter;

e. a derepressible p19 promoter;

f. a rep52 gene; and;

h. an antibiotic resistance gene.

2. The isolated nucleic acid molecule of claim 1 , wherein the cap gene is a cap gene from an AAV serotype selected from the group consisting of ANC80, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, and AAV11.

3. The isolated nucleic acid molecule of claim 2 , wherein the cap gene is an ANC80 cap gene.

4. The isolated nucleic acid molecule of claim 1 , wherein the derepressible p5 promoter comprises a functional p5 promoter and two tetracycline operator sequences (TetO 2 ).

5. The isolated nucleic acid molecule of claim 4 , wherein the derepressible p5 promoter comprises SEQ ID NO:5.

6. The isolated nucleic acid molecule of claim 1 , wherein the derepressible p19 promoter comprises a functional p19 promoter and two tetracycline operator sequences (TetO 2 ).

7. The isolated nucleic acid molecule of claim 6 , wherein the derepressible p19 promoter comprises SEQ ID NO: 7.

8. The isolated nucleic acid molecule of claim 1 , wherein the antibiotic resistance gene is a kanamycin resistance gene.

9. The isolated nucleic acid molecule of claim 1 , further comprising an inoperable antibiotic resistance gene.

10. An isolated nucleic acid molecule comprising a plasmid encoding, in operable order:

a. a derepressible p5 promoter comprising a functional p5 promoter and two tetracycline operator sequences (TetO 2 );

b. a rep78 gene, including a silenced p19 promoter located within the rep78 gene coding region, wherein the silenced p19 promoter comprises mutations in the SP1, TATA-1, and TATA-2 sites of a p19 promoter;

c. a viral associated (VA I) non-coding DNA;

d. a p5 promoter;

e. a derepressible p19 promoter comprising a functional p19 promoter and two tetracycline operator sequences (TetO 2 );

f. a rep52 gene; and;

h. an antibiotic resistance gene.

11. The isolated nucleic acid molecule of claim 10 , wherein the derepressible p5 promoter comprises SEQ ID NO:5.

12. The isolated nucleic acid molecule of claim 10 , wherein the derepressible p19 promoter comprises SEQ ID NO: 7.

13. The isolated nucleic acid molecule of claim 10 , wherein the antibiotic resistance gene is a kanamycin resistance gene.

14. The isolated nucleic acid molecule of claim 10 , further comprising an inoperable antibiotic resistance gene.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2020
From: GU, BINGNAN; GUENTHER, CAITLIN M.; SETH, ANANDITA
To: LONZA WALKERVILLE, INC.
Reel/Frame 051683/0586 →
Continuity (3)
Provisional Application 62866092 · Jun 25, 2019
Provisional Application 62783589 · Dec 21, 2018
Related Publication 20200199627A1 · Jun 25, 2020